B

BeOne

Global oncology therapeutics discovery, development, manufacturing

Marketing Director - Haematology, UK and Ireland

Full-Time
£104.9k - £131.1k/yr
Expert
Bachelor's
Remote in UK
RemoteRemote within the United Kingdom.
Growth & MarketingMarketing Generalist & Management

About the job

Requirements
  • University undergraduate degree in science or business
  • A minimum of 10 years of pharmaceutical industry marketing or related experience
  • UK marketplace launch experience required
  • Demonstrated success in a small but fast growing entrepreneurial commercial environment
  • Highly skilled in influencing cross-functional teams, including interfacing with key internal and external stakeholders and with scientific and commercial teams
  • Excellent interpersonal, oral and written communication skills, including ability to synthesize data and deliver a clear overview of commercial strategy, opportunity and risks for the Executive Team
  • Significant project management experience
  • Track-record of successful customer/HCP/KOL interactions
  • Excellent communication and presentation skills, both in person and virtual
  • Scientific + solution-oriented mindset and capability to move and execute in a rapidly changing, ambiguous environment
  • Willingness to travel (25%)
  • Fluency in both verbal and written English
  • Education Required: University undergraduate degree in science or business as a minimum; At least 10 years of relevant industry experience
  • Travel: Approximately 25% of time
  • Supervisory Responsibilities: Line management of one Associate Marketing Director, Haematology; Responsible for hiring, supervising and developing the team.
Responsibilities
  • Develop the overall Haematology strategy and tactical plans to support the UK and Ireland commercialisation of BeOne’s portfolio
  • Oversee all marketing strategies and plans in collaboration with BeOne global teams and commercialisation partners to realise maximal value in the UK and Ireland
  • Prepare the commercial market for the approval of BeOne’s future products in Haematology
  • Partner with Sales, Market Access and Medical Affairs to ensure alignment of BeOne’s UK and Ireland commercialisation strategy.
  • Collation and development of market insights that inform commercial strategies, tactics and product forecasts
  • Partner with Medical Affairs on the execution and development of an integrated scientific and thought leadership strategy.
  • Build strong partnerships with external partners and influence commercial strategy for partnered assets.
  • Localise and implement the strategy through various programs/channels (events, webinars, congresses, inbound, content syndication, direct mail, digital advertising etc.) including digital
  • Guide development of tactics to proactively address identified challenges/hurdles
  • Establish strong relationships and future-oriented collaborations with key opinion leaders (KOLs) and key accounts
  • Collaborate with key customers and patient advocates to develop relevant content in line with strategic objectives.
  • Guide development of promotional materials and activities
  • Steer impactful congress presence, communications and intelligence
  • Gain insights from market (HCPs, KOLs, patient groups) and identify therapeutic hurdles, opportunities and trends
  • Gather and interpret competitor intelligence
  • Partner with the field force to understand their resource gaps and opportunities through building strong relationships
  • Demonstrate marketing thought leadership and represents BeOne at key meetings and conferences, etc., when appropriate.
  • Oversee overall Haematology marketing budget ensuring appropriate spend and ROI on all marketing activities
Desired Qualifications
  • Specific knowledge and experience in the hematology market / knowledge in the field of lymphomas is highly desirable
  • Demonstrated success in a small but fast growing entrepreneurial commercial environment
  • Fluency in both verbal and written English

About the company

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Get referred to BeOne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 25, 2026 FDA approval expanded TEVIMBRA in first-line HER2-positive gastroesophageal cancer.
  • August 31, 2026 Phase 3 survival data strengthened ZIIHERA-containing regimens.
  • Q2 2026 revenue hit $1.7 billion; management raised 2026 guidance to $6.8 billion.

What critics are saying

  • BeOne accepted developed-market pricing parity and Medicaid rebates on future U.S. approvals.
  • Zydus' BRUKINSA ANDA lawsuit targets patents; a 2034 composition patent remains the fortress.
  • AbbVie's trade-secrets case over BGB-16673 still threatens the BTK-degrader franchise.

What makes BeOne unique

  • BeOne built 35-plus assets and 93 trials across 1,100 U.S. sites by September 2026.
  • BRUKINSA dominates revenue, with 2026 global sales above $1.2 billion quarterly.
  • Hopewell, New Jersey gives BeOne U.S. manufacturing, R&D, and packaging capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

8%

1 year growth

-6%

2 year growth

-1%
Associated Press
Oct 6th, 2026
Onco360 partners with BeOne Medicines to distribute Beqalzi for relapsed mantle cell lymphoma

Onco360, an independent specialty pharmacy, has been selected as a pharmacy partner by BeOne Medicines for Beqalzi (sonrotoclax). The drug is indicated for treating adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor. Beqalzi is a BCL-2 protein inhibitor. In a Phase 1/2 study of 103 adult patients with relapsed/refractory mantle cell lymphoma, the drug achieved an overall response rate of 52.4%, with a median time to response of 1.9 months. The median duration of response was 15.8 months. Onco360 is headquartered in Louisville, Kentucky, and operates as a flagship brand of PharMerica Corporation.

Yahoo Finance
Sep 4th, 2026
BeOne secures US pharma-tariff exemption after $1B+ manufacturing investment, but pricing concessions raise margin concerns

BeOne Medicines secured an exemption from Section 232 pharmaceutical tariffs through a voluntary agreement with the US government. The deal recognises over $1 billion in US manufacturing investment, including a $300 million expansion in Hopewell, New Jersey. The exemption protects BeOne from import duties on patented pharmaceuticals and ingredients. However, the company committed to pricing future FDA-approved medicines in line with other developed markets and participating in the Medicaid GENEROUS Model, which uses supplemental rebates. The Hopewell expansion will add small-molecule manufacturing and packaging capacity, creating approximately 120 full-time jobs. The facility will support a portfolio of more than 35 assets. Whilst the tariff exemption reduces supply-chain risk, international reference pricing commitments could limit pricing flexibility for future oncology medicines. Neither the tariff savings nor the financial impact of pricing concessions was disclosed.

Yahoo Finance
Aug 13th, 2026
Revolution Medicines shares rise 6.2% on BeOne-funded Phase 3 RAS(ON) deal

Revolution Medicines has partnered with BeOne Medicines in a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors. The August 2026 deal grants BeOne exclusive development and commercialisation rights in select Asian markets and commits BeOne to fund a global Phase 3 trial. Revolution Medicines reported a net loss of $644.37 million in Q2 2026 and $1.1 billion over six months. The company currently generates no revenue but projects $2.3 billion in revenue and $402.5 million in earnings by 2029. The partnership shifts near-term risk by offloading Phase 3 costs whilst providing access to milestone and royalty potential. However, the core investment case remains unchanged: regulatory progress and commercialisation of daraxonrasib, with trial execution and spending presenting the biggest risks.

Yahoo Finance
Aug 5th, 2026
BeOne Medicines Q2 revenue up 30% to $1.7B as BRUKINSA sales top $1.2B globally

BeOne Medicines reported second-quarter revenue of $1.7 billion, up 30% year over year, with GAAP earnings per ADS rising 144% to $2.05. The company's BTK inhibitor BRUKINSA generated more than $1.2 billion in global sales, increasing 31% from the prior year. The company raised its 2026 revenue guidance to CNY 6.6 billion–CNY 6.8 billion and expects GAAP operating income of CNY 1 billion–CNY 1.1 billion. Free cash flow doubled year over year to CNY 435 million. BeOne received FDA approval for Beqalzi in relapsed or refractory mantle cell lymphoma and reported positive Phase III results for a chemotherapy-free BRUKINSA regimen. US BRUKINSA sales totalled $893 million, up 31%, driven by demand in chronic lymphocytic leukaemia and non-CLL indications.

Yahoo Finance
Jul 23rd, 2026
BeOne CEO sells $34.6M in stock while retaining 50M+ shares

John Oyler, chief executive officer of BeOne Medicines AG, sold 109,713 American Depositary Shares worth $34.6 million on 20 and 21 July 2026, according to SEC filings. The transactions were executed under a Rule 10b5-1 trading plan adopted in March 2026. Despite the sale, Oyler retains a substantial ownership position exceeding 50.4 million total shares through various holdings. These include 28.2 million shares held through Oyler Investment LLC and 9.5 million shares in a Roth IRA account. The shares were sold at a weighted average price of $315.28. BeOne Medicines is a commercial-stage oncology biopharmaceutical company with $5.7 billion in trailing twelve-month revenue and a market capitalisation of $34.2 billion.